How can indigenously developed mRNA vaccines change India’s approach to controlling vector-borne diseases like Chikungunya?

Indigenously developed mRNA vaccines represent a significant leap forward for India’s public health sector, especially in tackling vector-borne diseases like Chikungunya. Unlike traditional vaccines, mRNA vaccines can be rapidly designed and produced, making them highly adaptable during outbreaks. The development of such vaccines within India can transform the country’s approach in several ways:

• Faster Response to Outbreaks: mRNA vaccine technology allows for quick adaptation to emerging strains of diseases like Chikungunya, enabling swift containment and reducing the spread.
• Self-Reliance and Reduced Import Dependence: Indigenous development reduces dependence on foreign vaccine suppliers, ensuring timely and affordable access for the Indian population.
• Cost-Effectiveness: Local manufacturing can lower production and distribution costs, making vaccines more accessible, especially in rural and remote areas.
• Customisation for Local Needs: Indian researchers can tailor vaccines to target strains prevalent in the country, improving efficacy and relevance.
• Strengthening Public Health Infrastructure: Developing and deploying mRNA vaccines domestically will boost research, manufacturing, and regulatory capabilities in India.
• Potential for Multi-Disease Platforms: mRNA technology can be adapted quickly for other vector-borne diseases like Dengue or Zika, supporting a more comprehensive disease control strategy.
• Improved Public Confidence: Homegrown vaccines may increase public trust and acceptance, leading to higher vaccination coverage.